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1. Summary of the impact (indicative maximum 100 words) 
Steered by Professor David Fell of Oxford Brookes University, Physiomics plc, an Oxford-based 
biotechnology innovation company has, since 2008, firmly established itself as a leading light in 
systems biology approaches to drug discovery and latterly in therapy design, demonstrable 
through contracts with three major international pharmaceutical companies. Through its strong 
advocacy of this approach the sector has invested in and adopted new computational biology 
processes. As Physiomics has continued to grow, it has expanded its own specialist research 
team, in many cases recruiting scientists trained within Fell‟s Brookes-based research group. 
 
2. Underpinning research (indicative maximum 500 words) 
For many years, Professor David Fell and colleagues at Oxford Brookes University have been 
researching computer modelling of biochemistry, primarily metabolism and its regulation of 
metabolism, but also signal transduction (the signalling from outside the cell to affect what happens 
within it). 
The sequencing of the human genome has transformed biology, but that for the most part, the 
tools needed to understand and use this information are still at an early stage.  This has triggered 
important developments in bioinformatics, systems biology, and computational biology.  In general, 
the tools for analysing the data (bioinformatics) have progressed faster than the tools for using the 
predictive power of the data (modelling). 
Through various research studies funded by Oxford Brookes University between 1994 and 2001, 
the Fell laboratory has developed new methods and concepts in the control of metabolism and the 
analysis of metabolic networks.  For example, the study of sites and mechanisms of control in 
metabolism and signal transduction has a direct relevance to the action of drugs [1-4].  Along with 
this, the group developed its own software for the modelling and analysis of metabolic networks.  
One of these programs, SCAMP, was further developed and refined in the late 1990s.  It was used 
as a major tool throughout the investigations described in the subsequent papers from 2001 
onwards [3-5]. This later version became the foundation of the Physiomics applications. 
Four papers on kinetic modelling of enzyme networks are cited as examples of the underpinning 
research; 
Kashiwaya et al (1994) [1] exemplifies the development of expertise in the analysis of the control of 
metabolism.  Fell and Thomas (PGRA on a SERC research grant) provided the theoretical 
interpretation to experiments on the control of heart metabolism by insulin carried out by the Veech 
& Passonneau group. 
Brightman & Fell (2000) [2] is based on Frances Brightman's PhD work at Oxford Brookes, 
modelling the signal transduction pathway for Epidermal Growth Factor, abnormalities of which are 
common in certain types of tumour.  It was one of the first detailed models of this important 
pathway and has been reused and developed by other researchers. 
Chassagnole et al, (2001a) [3] and (2001b) [4] both concern modelling of the pathway of threonine 
synthesis in the bacterium Escherischia coli.  The laboratory research on which this paper is based 
was carried out by Christophe Chassagnole in Prof Mazat's lab at the University of Bordeaux II, 
and Fell started the construction of a computer simulation during a sabbatical term in 1997 and 
taught Chassagnole the data fitting and simulation techniques, which then continued 
collaboratively. 
The combination of the research approaches in Fell‟s group and its application to drug 
development issues is illustrated by the joint publication with Jackson (2006) [5] which explores the 
overall effect of a series of drug candidates that have different degrees of specificity for their 
intended target and other „off-target‟ molecules. 
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Joint publication with Physiomics and Cyclacel Pharmaceuticals on modelling actions of drug 
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4. Details of the impact (indicative maximum 750 words) 
There are a number of excellent academic groups in the computational biology area, relatively few 
such groups in industry.  Most industrial biologists have limited mathematical skills and training, 
while most academic bio-mathematicians do not work in collaboration with experimental biologists.  
Fell‟s team at Brookes are one of the very few groups attempting to close this gap.  Their impact 
falls into two main areas; through Fell‟s involvement with Physiomics as Chief Scientific Adviser, 
they are making powerful modelling tools available to industry; secondly, by training students at 
Brookes who use modelling tools with systems biology data, they are helping to provide the basis 
for a more mathematically literate workforce in industrial biology. 
In 2001, an independent biotech analyst, John Savin had the idea of using computer modelling of 
cellular processes to improve the drug development pipeline.  He identified Fell‟s research as 
exemplifying the concept he had.  An investor was found and Physiomics plc was founded 
independently of Brookes.  In the period 2001-2004 Fell was Science Director of Physiomics and 
from 2005 has been Chief Scientific Adviser attending monthly R & D meetings and Scientific 
Advisory Boards (3 per year).  Both roles have been facilitated through a consultancy agreement 
with Brookes. 
Software for running modelling of biological systems was developed which was used as a 
demonstration for pharmaceutical companies to try to attract further R&D funding for the systems 
biology approach to identify targets. Building upon the SCAMP programme, the models of 
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threonine synthesis and EGF signal transduction described above [2-4] were used to test the 
Physiomics software. 
Physiomics‟ first major contract was won in 2004 with Bayer Technical Services, and interest from 
companies undertaking cancer drug development followed, including Cyclacel in Dundee.  
Since 2008, Physiomics has secured contracts with major players in the pharmaceutical sector, 
which demonstrates they have adopted a new systems approach to drug development and therapy 
design.  This can be demonstrated by the numerous contracts which have been reported upon in 
Physiomics‟ Annual Reports [a] and Physiomics‟ News & Events pages [b] and specific press 
releases including the collaboration with Pharmacometrics Ltd, May 2011 [c] (joint development of 
DrugCARD database).  Building on its work on predicting drug effects on cells, Physiomics has 
added therapy design to its capabilities, in which the effects of combination drug therapies on 
tumours are modelled and trialled on the software and the best combination is chosen using the 
predicted effect.  This approach has been demonstrated to be successful in trials funded by Eli Lilly 
in 2011 [d], in which the results were compared with a trial that used the traditional mouse 
xenograft model.  The software correctly predicted the outcome in 19 out of 21 cases [e].  This 
indicates huge potential in the reduction in trial costs as the modelling can be run in 4-6 weeks 
instead of 6 months, and no costs are incurred associated with the animals.  This successful trial 
has resulted in two further contracts with a major global pharmaceutical company, March 2012 [f] 
and a top-five pharmaceutical company Aug 2012 [g] (names withheld by agreement with the 
companies).  Additional contracts of a therapeutic design focus include: 
 ValiRx plc, September 2011 [h] 
 Eli Lilly, November 2011 [i] 
 Sareum, The Institute of Cancer Research (ICR) and Cancer Research Technology Limited 
(CRT) joint programme, March 2012 [j] 
 
These contracts demonstrate that the field of systems biology and the modelling approaches 
pioneered through the work of the Fell research group at Brookes, now form an integral part of the 
latest approaches to drug discovery and therapeutic design; thus a sector has adopted a new 
process and technology. Research and Development spending in the three-year period of 2010 to 
2012 was £565k, more than double that of the period 2006 to 2008 at £246K. Similarly, the net 
Share Capital raised in the same periods also more than tripled from £621K to £2.2million [a]. 
Furthermore, Physiomics has succeeded in its strategic aim of diversifying the applications of its 
technology beyond drug development and therapeutic design, as demonstrated in the 2010 
contract with the Carbon Trust, in collaboration with Green Biologics which involved metabolic 
modelling of butanol formation in order to optimise its production from waste as a viable fuel source 
[k]. 
Brookes has trained a number of the Physiomics staff working on these contracts including 
Brightman who is still employed at Physiomics. Others who have since moved on include Lubna 
Bashir, Nazia Hussain, and Cathy Derow (who has returned to Brookes to undertake a PhD).  
Christophe Cassagnole from the Mazat collaborating lab., joined Physiomics in 2004 and became 
Chief Operating Officer in 2007 [b]. 
 
5. Sources to corroborate the impact (indicative maximum of 10 references) 
 
[a] Physiomics Annual Reports 2004 to present.  Available from http://www.physiomics-
plc.com/investors/reports-prospectus/ 
[b] Physiomics Plc „News & Events‟ http://www.physiomics-plc.com/news-events/ 
[c] „New collaboration with Pharmacometrics‟ http://www.digitallook.com/news/rns/4209197-
104396/PYC-New_collaboration_with_Pharmacometrics_Limited_html  
[d] „Virtual Tumour Preclinical - Physiomics Virtual Tumour technology‟ http://www.physiomics-
plc.com/services/schedules-and-combinations/ 
[e] „Results Update – Virtual Tumour‟ 1 April 2011 http://www.physiomics-plc.com/results-update-
%E2%80%93-virtual-tumour/ 
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[f] „New Agreement to advance oncology candidate with global pharma company‟ 1 March 2012 
http://www.physiomics-plc.com/wp-content/uploads/downloads/2012/03/New-Agreement-to-
advance-oncology-candidate-with-global-pharma-company-01-03-12.pdf 
[g] „New Agreement to optimise oncology combination with top five pharma company‟ 10 August 
2012 http://www.physiomics-plc.com/wp-content/uploads/downloads/2012/08/New-Agreement-
to-optimise-oncology-combination-with-top-five-pharma-company-10-08-12.pdf 
[h] “ValiRx to use Physiomics‟ Virtual Tumour technology to accelerate development of promising 
prostate cancer drug”http://www.valirx.com/media_files/ValiRx_Plc_-
_Physiomics_Collaborative_Agreement.pdf 
[i] „Physiomics shares up 24 pct after new deal with Eli Lilly‟ Giles Gwinnett, 2 November 2011 
http://www.proactiveinvestors.co.uk/companies/news/35090 
[j] „Physiomics to Collaborate with Sareum, the ICR and CRT on Cancer Drug Development 
Programme‟ 16 March 2010 
http://www.icr.ac.uk/press/press_archive/press_releases_2010/14959.shtml 
[k] „Green Biologics and Physiomics Receive Grant‟ 16 November 2010 
http://www.obn.org.uk/obn_/news_item.php?r=OJK7KR124701  
 
 
